MCID: LCH002
MIFTS: 54

Lichen Planus

Categories: Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lichen Planus

MalaCards integrated aliases for Lichen Planus:

Name: Lichen Planus 11 75 53 43 14 16 71 31 33
Lichen Ruber Planus 11 33
Lichen Planus of Wilson 33
Lichen, Ruber Planus 11
Lp - [lichen Planus] 33
Wilson Lichen Ruber 33
Ruber Planus 33

Classifications:



External Ids:

Disease Ontology 11 DOID:9201
ICD9CM 34 697.0
MeSH 43 D008010
NCIt 49 C3189
SNOMED-CT 68 156377007
ICD10 31 L43 L43.9
UMLS 71 C0023646

Summaries for Lichen Planus

Disease Ontology: 11 A lichen disease that is located in skin, located in tongue or located in oral mucosa, which presents itself in the form of papules, lesions or rashes.

MalaCards based summary: Lichen Planus, also known as lichen ruber planus, is related to alopecia and stomatitis, and has symptoms including pruritus An important gene associated with Lichen Planus is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are Extracellular matrix organization and COPI-independent Golgi-to-ER retrograde traffic. The drugs Triamcinolone and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and thyroid, and related phenotypes are Increased gamma-H2AX phosphorylation and growth/size/body region

Wikipedia: 75 Lichen planus (LP) is a chronic inflammatory and immune-mediated disease that affects the skin, nails,... more...

Related Diseases for Lichen Planus

Diseases in the Lichen Planus family:

Lichen Planus, Familial Rare Lichen Planus

Diseases related to Lichen Planus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 759)
# Related Disease Score Top Affiliating Genes
1 alopecia 31.7 TNF IFNG FLG COL17A1
2 stomatitis 31.5 TNF MX1 IFNG
3 pemphigoid 31.5 TNF IFNG DST DSG3 COL17A1
4 leukoplakia 31.5 KRT13 KRT1 FLG DEFB4A
5 candidiasis 31.4 TNF IFNG DEFB4A
6 gingivitis 31.4 TNF IFNG ICAM1 DEFB4A
7 viral infectious disease 31.4 TNF MX1 IFNG ICAM1 GZMB CXCR3
8 pemphigus 31.3 TNF DST DSG3 COL17A1
9 autoimmune disease 31.2 TNF ITGAL IFNG ICAM1 DSG3 CXCR3
10 lip and oral cavity cancer 31.2 MIR31 KRT13 IVL
11 erythema multiforme 31.1 TNF IFNG ICAM1 GZMB
12 periodontitis 31.1 TNF IFNG ICAM1 DEFB4A
13 aphthous stomatitis 31.1 TNF IFNG DSG3
14 bullous pemphigoid 31.1 TNF LAMC2 IVL DST DSG3 COL17A1
15 viral hepatitis 31.0 MX1 ITGAL IFNG ICAM1
16 fungal infectious disease 31.0 TNF IFNG DEFB4A
17 paraneoplastic pemphigus 31.0 DST DSG3 COL17A1
18 hashimoto thyroiditis 31.0 ITGAL IFNG ICAM1 CXCR3
19 keratoconjunctivitis 31.0 TNF ITGAL IFNG ICAM1
20 conjunctivitis 30.9 TNF IFNG ICAM1 CXCL9
21 metal allergy 30.9 TNF FLG
22 pemphigus vulgaris, familial 30.9 IVL DST DSG3 COL17A1
23 allergic disease 30.9 TNF IFNG ICAM1 GZMB FLG
24 acute graft versus host disease 30.9 TNF IFNG
25 erythema nodosum 30.9 TNF IFNG ICAM1
26 severe cutaneous adverse reaction 30.9 TNF KRT13 IFNG GZMB
27 celiac disease 1 30.8 TNF IFNG GZMB CXCR3
28 proteasome-associated autoinflammatory syndrome 1 30.8 TNF IFNG ICAM1
29 scabies 30.8 FLG DST COL17A1
30 seborrheic dermatitis 30.8 TNF FLG DEFB4A
31 cicatricial pemphigoid 30.8 LAMC2 KRT13 DST DSG3 COL17A1
32 cryoglobulinemia 30.7 TNF IFNG CXCL9
33 hidradenitis suppurativa 30.7 TNF KRT10 IFNG
34 epidermolysis bullosa acquisita 30.7 LAMC2 DST COL17A1
35 hidradenitis 30.7 TNF IFNG DSG3
36 actinic keratosis 30.6 TNF KRT10 IVL FLG
37 acne 30.6 TNF FLG DEFB4A
38 sarcoidosis 1 30.6 TNF IFNG ICAM1 CXCR3 CXCL9
39 pemphigoid gestationis 30.6 DST DSG3 COL17A1
40 pustular psoriasis 30.6 TNF IFNG CXCL9
41 papilloma 30.5 KRT13 KRT10 KRT1 IVL FLG
42 food allergy 30.5 TNF IFNG FLG
43 mumps 30.5 TNF MX1 IFNG
44 nevus, epidermal 30.5 KRT10 KRT1 IVL
45 severe acute respiratory syndrome 30.5 TNF MX1 IFNG CXCL9
46 keratosis 30.4 KRT16 KRT10 KRT1 IVL FLG DST
47 poliomyelitis 30.4 TNF IFNG ICAM1
48 skin sarcoidosis 30.4 TNF IFNG
49 folliculitis 30.4 TNF IFNG DEFB4A
50 dermatitis, atopic 30.4 TNF IVL IFNG ICAM1 FLG DEFB4A

Graphical network of the top 20 diseases related to Lichen Planus:



Diseases related to Lichen Planus

Symptoms & Phenotypes for Lichen Planus

UMLS symptoms related to Lichen Planus:


pruritus

GenomeRNAi Phenotypes related to Lichen Planus according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased gamma-H2AX phosphorylation GR00053-A 9.32 COL17A1 CXCL9 CXCR3 DEFB4A DSG3 IVL

MGI Mouse Phenotypes related to Lichen Planus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.22 COL17A1 DSG3 DST ICAM1 IFNG IVL
2 immune system MP:0005387 10.13 COL17A1 CXCL9 CXCR3 DEFB4A DSG3 DST
3 neoplasm MP:0002006 10.03 CXCR3 GZMB ICAM1 IFNG ITGAL KRT10
4 digestive/alimentary MP:0005381 9.97 DSG3 DST ICAM1 IFNG KRT13 KRT16
5 hematopoietic system MP:0005397 9.97 COL17A1 CXCL9 CXCR3 DEFB4A DSG3 DST
6 craniofacial MP:0005382 9.92 DSG3 DST IFNG KRT10 KRT13 KRT16
7 mortality/aging MP:0010768 9.83 COL17A1 CXCL9 CXCR3 DSG3 DST GZMB
8 integument MP:0010771 9.36 COL17A1 DSG3 DST ICAM1 IFNG KRT1

Drugs & Therapeutics for Lichen Planus

Drugs for Lichen Planus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
4
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
7
Lycopene Approved, Investigational Phase 4 502-65-8 446925
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
13
Lactitol Approved, Investigational Phase 4 585-86-4 157355
14
Glucosamine Approved, Investigational Phase 4 3416-24-8 318324 439213
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Pomegranate Experimental, Investigational Phase 4
17
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
18
Chitosan low molecular weight (20-200 mpa.s) Experimental Phase 4 14257-69-3, 9012-76-4 441477 71853
19 Antioxidants Phase 4
20 Protective Agents Phase 4
21
Triamcinolone hexacetonide Phase 4
22
Triamcinolone diacetate Phase 4
23
Triamcinolone Acetonide Phase 4 6436
24 Hormones Phase 4
25 Hormone Antagonists Phase 4
26 glucocorticoids Phase 4
27 Anti-Asthmatic Agents Phase 4
28 Betamethasone-17,21-dipropionate Phase 4
29
Betamethasone Valerate Phase 4 2152-44-5
30
Betamethasone sodium phosphate Phase 4
31
Betamethasone benzoate Phase 4
32 Respiratory System Agents Phase 4
33 Radiation-Protective Agents Phase 4
34 Antifungal Agents Phase 4
35
Methylprednisolone Acetate Phase 4 584547
36 Anesthetics Phase 4
37 Anesthetics, Local Phase 4
38 Anti-Arrhythmia Agents Phase 4
39 Sodium Channel Blockers Phase 4
40 Diuretics, Potassium Sparing Phase 4
41
Minocycline Approved, Investigational Phase 3 10118-90-8, 13614-98-7 54675783 5281021
42 Tomato Approved Phase 2, Phase 3
43
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
44
Fluoxymesterone Approved, Illicit Phase 2, Phase 3 76-43-7 6446
45
Clobetasol Approved, Experimental, Investigational Phase 2, Phase 3 25122-46-7, 25122-41-2 2791 5311051 32798
46
Nystatin Approved, Vet_approved Phase 2, Phase 3 1400-61-9 11953884
47
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
48
Petrolatum Approved, Investigational Phase 3 8009-03-8
49 Anti-Inflammatory Agents Phase 2, Phase 3
50 Tea Phase 3

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Comparative Evaluation of Effect of Oral Zinc Supplementation and Placebo as an Adjuvant to Topical Corticosteroid Therapy in Oral Lichen Planus Patients Unknown status NCT04278599 Phase 4 Oral Zinc supplementation;Oral placebo supplementation
2 Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial) Completed NCT04193748 Phase 4 Topical pomegranate seeds and peel extracts
3 Comparative Study of the Efficacy of Lycopene Versus Prednisolone in the Management of Oral Lichen Planus: A Randomized, Double Blind Clinical Trial Completed NCT02587117 Phase 4 lycopene;Prednisolone
4 Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus ( A Randomized Controlled Clinical Trial With Immunohistochemical Analysis) Completed NCT05139667 Phase 4 Corticosteroid Topical
5 Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
6 A Comparative Clinical and Immunohistochemical Study Between Topical Pimecrolimus and Corticosteroid in Treatment of Oral Lichen Planus Completed NCT02443311 Phase 4 Pimecrolimus 1% cream;Betamethasone 17-valerate 0.1% cream
7 Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus: A Pilot, Randomized, Clinical and Immunohistochemical Trial Completed NCT02858297 Phase 4 Glucosamine sulfate;triamcinolone acetonide
8 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
9 The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus. A Randomized Controlled Trial Unknown status NCT01083420 Phase 3 Minocycline;Dexamethasone
10 Evaluation of Lycopene in the Treatment of Erosive Oral Lichen Planus (A Randomized Clinical Trial) Completed NCT04652739 Phase 2, Phase 3 Lycopene Softgel, 10 Mg;Prednisolone
11 Randomized Placebo-Controlled Clinical Pilot Trial Regarding the Efficacy of Elidel Cream on Erosive Oral Lichen Planus Completed NCT00130572 Phase 3 Pimecrolimus
12 Chamaemelum Nobile 2% Versus Placebo Topic Gel to Treatment Oral LichenPlanus Completed NCT02421770 Phase 3
13 Evaluation of Systemic Administration of Green Tea Polyphenols as a Supportive Antioxidant Agent in the Management of Oral Lichen Planus Completed NCT02329600 Phase 3 green tea tablets (Green tea extract 5:1) 200 mg;Triamcinolone Acetonide
14 Use of Topical Non-Steroidal Anti- Inflammatory to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions. Completed NCT03509675 Phase 2, Phase 3 Ibuprofen suspension 5mg/100ml;Placebos
15 A Study of Topical Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) and a Phase III Comparative Treatment Study of HAL PDT in Female Genital Erosive Lichen Planus (GELP) Completed NCT01282515 Phase 2, Phase 3 clobetasol propionate 0,05% ointment;hexaminolevulinate
16 Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. A Multicenter Placebo-controlled Randomized Clinical Trial. Recruiting NCT04364555 Phase 2, Phase 3 Clobetasol Propionate;Placebo/Klobetasol APL oral gel 0.025%;Placebo
17 Efficacy of Topical Rapamycin in Treatment of Chronic Erosive Oral Lichen Planus. Double Blind Randomised Controlled Trial Rapamycin vs Topical Steroids Terminated NCT01061853 Phase 3 TOPICAL SIROLIMUS (RAPAMUNE*);TOPICAL BETAMETHASONE 0.05%
18 Efficacy of Intralesional Injection of Autologous Platelet Rich Plasma Versus Intralesional Injection of Corticosteroids on Pain Relief and Ulcers Healing in Patients With Erosive Oral Lichen Planus; Randomized Clinical Trial Unknown status NCT03293368 Phase 2 Triamcinolone Acetonide
19 A Comparative Study on Clinical Efficacy of Clobetasol and Betamethasone in Orabase in Combination With Clotrimazole, in Oral Lichen Planus Unknown status NCT03026478 Phase 2 Betamethasone Dipropionate;Clobetasol Propionate
20 A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus Unknown status NCT01524744 Phase 2 Pimecrolimus ointment;Adcortyl
21 An Open-Label Pilot Study to Evaluate the Safety and Efficacy of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus Unknown status NCT01041625 Phase 2 Apremilast (CC-10004)
22 Single-Center, Prospective, Open Label, Single-arm Pilot Study Investigating the Efficacy and Safety of Alitretinoin in Patients Suffering From Severe Mucosal Lichen Planus. Unknown status NCT01538732 Phase 2 alitretinoin
23 A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE Completed NCT04300296 Phase 2 Cutaneous lichen planus secukinumab 300 mg Q4W;Cutaneous lichen planus placebo;Mucosal lichen planus placebo;Lichen planopilaris placebo;Mucosal lichen planus secukinumab 300 mg Q4W;Lichen planopilaris secukinumab 300 mg Q4W
24 Treatment of Oral Lichen Planus Lesions Completed NCT00746772 Phase 2 Purslane 235mg/day in one dosage;Placebo : one dosage
25 Cedar Honey in Treatment of Oral Lichen Planus: a Randomized Clinical Trial Completed NCT01974414 Phase 1, Phase 2 orally administered cedar honey
26 Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other Completed NCT00484250 Phase 2 metronidazole,doxycycline
27 Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus- A Double-blinded Randomized Clinical Trial in Sri Lanka Completed NCT02744378 Phase 2 Tacrolimus 0.1%;Clobetasol 0.05%
28 Efficacy of Oral Lycopene in the Management of Oral Lichen Planus Completed NCT00656214 Phase 2 Lycopene;Placebo
29 The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus and Improvement of Quality of Life: A Randomized, Double Blind, Controlled Study Completed NCT02106468 Phase 2 Prednisone tablet 5mg;Omega-3 soft capsules 1000 mg
30 A Randomized, Placebo-Controlled, Double-Blind Trial of a Two Week Course of Curcuminoids in Oral Lichen Planus Completed NCT00525421 Phase 2 Curcuminoids;Placebo
31 Effect of the Probiotic Bifidobacterium Animalis Subsp. Lactis HN019 on Clinical, Histopathological and Immunophenotypic Features of Oral Lichen Planus Completed NCT03386643 Phase 2 Bifidobacterium animalis subsp. lactis HN019;Clobetasol propionate 0.05%
32 Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on the Duration and Symptoms of Lesions That Caused by Symptomatic Oral Lichen Planus Completed NCT02453503 Phase 2 Licorice;Triamcinolone Acetonide
33 A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate When Administered Intra-orally Twice Daily in Patients With Oral Lichen Planus (OLP) Using Rivelin®-CLO Patches Completed NCT03592342 Phase 2 Clobetasol Propionate
34 A 6-week Randomized, Double-blind, Vehicle-controlled Pilot Study With a 6-week Open Label Extension to Assess the Efficacy and Safety of Pimecrolimus 1% Cream in the Treatment of Oral Lichen Planus Completed NCT00297037 Phase 2 Pimecrolimus 1% cream
35 Dexamethasone 0.01% Solution for the Treatment of Oral Lichen Planus Completed NCT00111072 Phase 2 dexamethasone 0.01% solution
36 Hydroxychloroquine Versus Clobetasol 0.05% Rinse for the Treatment of Oral Lichen Planus Completed NCT00102557 Phase 2 Hydroxychloroquine
37 Evaluation of the Effectiveness of Photodynamic Therapy in the Treatment of Lesions of the Lichen Planus Type in the Oral Mucosa and Its Diagnostics With the Use of Autofluorescence, in Various Wavelength Ranges, in Combination With the Use of Texture Analysis and Fractal Dimension Completed NCT04991012 Phase 2 Triamcinolone (Substance) therapy side
38 A Comparison of Clinical Efficiency of Photodynamic Therapy and Topical Corticosteroid in Treatment of Oral Lichen Planus- Split-Mouth Randomised Completed NCT04976673 Phase 2 Triamcinolone Acetonide
39 Nonaromatic Naphthalan - Composition Study and Biological Effects on Epithelial Tissues Completed NCT02920658 Phase 2 NAVS Naphthalan;0.05% Betamethasone dipropionate
40 Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Lichen Planus Completed NCT02850601 Phase 2 Dexamethasone
41 INCB018424 in the Treatment of Cutaneous Lichen Planus Completed NCT03697460 Phase 2 INCB018424
42 KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus Completed NCT03858634 Phase 2 KPL-716;Placebo
43 Valchlor in the Treatment of Lichen Planopilaris: A Single Arm, Open- Label, Exploratory Study Completed NCT03417141 Phase 2 Mechlorethamine 0.016% Top Gel
44 Oral Low-Dose Naltrexone in the Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia; an Uncontrolled Open-label Prospective Study Completed NCT04409041 Phase 2 Low-Dose Naltrexone
45 Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases Recruiting NCT04540133 Phase 2 dexamethasone 0.5mg/5ml solution;dexamethasone 0.5mg/5ml solution in Mucolox™
46 A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus Recruiting NCT05593432 Phase 2 Ruxolitinib cream;Vehicle cream
47 The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans Recruiting NCT04233749 Phase 2 Tranexamic acid tablets
48 The AP-GELP Study: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Phosphodiesterase 4-Inhibitor Apremilast in Female Genital Erosive Lichen Planus Recruiting NCT03656666 Phase 2 Apremilast;Placebo
49 Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus Recruiting NCT05188521 Phase 2 Baricitinib (LY3009104)
50 A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Curcuminoids in Oral Lichen Planus Terminated NCT00226174 Phase 2 Curcuminoids

Search NIH Clinical Center for Lichen Planus

Cochrane evidence based reviews: lichen planus

Genetic Tests for Lichen Planus

Anatomical Context for Lichen Planus

Organs/tissues related to Lichen Planus:

FMA: Skin, Tongue
MalaCards : Skin, Tongue, Thyroid, T Cells, Liver, Bone Marrow, Salivary Gland

Publications for Lichen Planus

Articles related to Lichen Planus:

(show top 50) (show all 8671)
# Title Authors PMID Year
1
T cells reactive with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus. 53 62
19686329 2010
2
Involvement of granzyme B and granulysin in the cytotoxic response in lichen planus. 53 62
18331568 2008
3
The expression of TNF-alpha and ICAM-1 in lesions of lichen planus and its implication. 53 62
18231758 2007
4
Cytokine alterations in lichen sclerosus: an immunohistochemical study. 53 62
17034521 2006
5
Collagen XVII/BP180: a collagenous transmembrane protein and component of the dermoepidermal anchoring complex. 53 62
16197389 2005
6
Cytotoxic molecule expression and epithelial cell apoptosis in oral and cutaneous lichen planus. 53 62
15151217 2004
7
Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. 53 62
12705750 2003
8
Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. 53 62
12373334 2002
9
Oral lichen planus: an update. 53 62
12582419 2002
10
Topical retinaldehyde treatment in oral lichen planus and leukoplakia. 53 62
12779246 2002
11
Upregulation of human beta-defensin 2 peptide expression in oral lichen planus, leukoplakia and candidiasis. an immunohistochemical study. 53 62
12389997 2002
12
Identification of the AgNORs, PCNA and ck16 proteins in oral lichen planus lesions. 53 62
11834097 2001
13
Presence of lichen planus during a course of interferon alpha-2a therapy for a viral chronic C hepatitis. 53 62
11694869 2001
14
Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. 53 62
11523046 2001
15
Lichen planus exacerbation by interferon-alpha-2A for chronic viral hepatitis C. 53 62
19864712 2000
16
Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? 53 62
10815859 2000
17
Lichen planus induced by interferon-alpha-2B therapy in a patient with cutaneous malignant melanoma. 53 62
10494726 1999
18
Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. 53 62
10417629 1999
19
Acquired skin disease of hemidesmosomes. 53 62
10379705 1999
20
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 53 62
10233762 1999
21
BP180/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. 53 62
10335914 1999
22
C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. 53 62
10027407 1999
23
MIG is a dominant lymphocyte-attractant chemokine in lichen planus lesions. 53 62
9856808 1998
24
The role of granzyme B-expressing CD8-positive T cells in apoptosis of keratinocytes in lichen planus. 53 62
9341973 1997
25
Keratin and involucrin expression in discoid lupus erythematosus and lichen planus. 53 62
9341972 1997
26
Altered distribution and synthesis of laminin-5 (kalinin) in oral lichen planus, epithelial dysplasias and squamous cell carcinomas. 53 62
9115910 1997
27
Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. 53 62
8864684 1996
28
Vascular adhesion molecules in oral lichen planus. 53 62
8784900 1996
29
Destruction of the epithelial anchoring system in lichen planus. 53 62
7615961 1995
30
In three types of interface dermatitis, different patterns of expression of intercellular adhesion molecule-1 (ICAM-1) indicate different triggers of disease. 53 62
7616001 1995
31
Lichen planus induced by interferon-alpha-2a therapy for chronic active hepatitis C. 53 62
7600144 1995
32
Alteration of cytokeratin expression in oral lichen planus. 53 62
7542150 1995
33
Expression of MxA protein in inflammatory dermatoses. 53 62
7822763 1995
34
Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme-histochemical staining techniques. 53 62
7538409 1994
35
Immunofluorescent analysis of the basement membrane zone in lichen planus suggests destruction of the lamina lucida in bullous lesions. 53 62
8040461 1994
36
Increased submucosal factor XIIIa-positive dendrocytes in oral lichen planus. 53 62
7517451 1994
37
Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus. 53 62
8100122 1993
38
Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: in situ expression of beta 2-integrins. 53 62
1401271 1992
39
Expression of the CD54 (ICAM-1) and CD11a (LFA-1) adhesion molecules in oral mucosal inflammation. 53 62
1348286 1992
40
Elastolysis in lichen ruber planus. 53 62
1681662 1991
41
[Lichen planus: etiopathogenesis]. 53 62
1983174 1990
42
Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. 53 62
2258627 1990
43
Induction and upregulation of adhesion receptors in oral and dermal lichen planus. 53 62
1981078 1990
44
Lichen planus pemphigoides: case report and results of immunofluorescence and immunoelectron microscopic study. 53 62
2180994 1990
45
Immunohistochemical studies on fibrillin in amyloidosis, lichen ruber planus and porphyria. 53 62
1699374 1990
46
Etretinate suppresses ICAM-1 expression by lesional keratinocytes in healing cutaneous lichen planus. 53 62
1979727 1990
47
Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab. 62
36439781 2022
48
Laryngeal lichen planus mimicking vocal fold dysplasia. 62
33965285 2022
49
Will there be a critical review on the malignant transformation of oral lichen planus? 62
36473365 2022
50
Association of autoimmune comorbidities with lichen planus: A United States-based case-control study in the All of Us research program. 62
35931217 2022

Variations for Lichen Planus

Expression for Lichen Planus

Search GEO for disease gene expression data for Lichen Planus.

Pathways for Lichen Planus

Pathways related to Lichen Planus according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.5 LAMC2 ITGAL ICAM1 DST COL17A1
2
Show member pathways
12.33 KRT16 KRT13 KRT1 DST
3
Show member pathways
11.71 KRT16 KRT13 KRT10 KRT1 IVL FLG
4 11.56 TNF ICAM1 FLG
5
Show member pathways
11.47 TNF IFNG ICAM1
6 11.45 TNF ICAM1 GZMB
7 11.43 TNF IFNG GZMB CXCL9
8 11.32 DEFB4A IFNG TNF
9 11.22 ITGAL IFNG ICAM1
10 11.16 TNF IFNG GZMB CXCR3
11 11.11 IFNG ICAM1 CXCL9
12
Show member pathways
11.05 TNF IFNG GZMB
13 10.86 TNF IFNG GZMB
14 10.83 TNF LAMC2 ITGAL CXCL9 COL17A1
15 10.75 TNF ICAM1

GO Terms for Lichen Planus

Cellular components related to Lichen Planus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.13 COL17A1 CXCL9 DEFB4A ICAM1 IFNG KRT1
2 hemidesmosome GO:0030056 9.56 DST COL17A1
3 intermediate filament GO:0005882 9.56 KRT16 KRT13 KRT10 KRT1 DST
4 cornified envelope GO:0001533 9.4 KRT16 KRT10 KRT1 IVL FLG DSG3

Biological processes related to Lichen Planus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response GO:0006952 9.91 TNF MX1 DEFB4A CXCL9
2 establishment of skin barrier GO:0061436 9.85 KRT16 KRT1 FLG
3 hemidesmosome assembly GO:0031581 9.76 DST COL17A1
4 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell GO:0002291 9.71 ITGAL ICAM1
5 positive regulation of nitrogen compound metabolic process GO:0051173 9.62 IFNG TNF
6 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 IFNG TNF
7 keratinocyte differentiation GO:0030216 9.56 KRT16 KRT10 IVL FLG
8 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 TNF IFNG
9 peptide cross-linking GO:0018149 9.23 KRT10 KRT1 IVL FLG

Molecular functions related to Lichen Planus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of skin epidermis GO:0030280 9.43 KRT10 KRT1 FLG
2 structural molecule activity GO:0005198 9.17 KRT16 KRT13 KRT10 FLG DST

Sources for Lichen Planus

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....